Glioblastoma, IDH-wildtype (GBM), unpredictably invades the brain, making it difficult for clinicians to predict the appropriate therapy. Additionally, due to its aggressive neuroinvasion, patients’ responses to treatment vary widely, rendering “one therapy for all” ineffective. Thus, GBM is fatal, with no promising cure. The median survival time for GBM patients is 15 months from the time of initial diagnosis. Traditional mouse xenografts used to predict neuroinvasion take time to develop tumours, often after the patient has died, making personalised medicine for GBM impossible. To overcome these limitations, in our Glioma-PerMed consortium, we utilise 3D human brain organoids (brain-like tissues) and zebrafish to predict patient-specific GBM invasion patterns reliably. Using a Bed-to-Benchside approach, we generate GBM tumoroids and perform invasion assays with AI-based high-content imaging. Through this method, we can predict invasion patterns within 30-40 days after surgery and identify EMA/FDA-approved drugs that target GBM invasion.

To disseminate this knowledge and realise personalised glioma medicine, we bring together neurosurgeons, in vivo and multi-omics experimentalists, stem cell, chemical, and computational biologists, tissue engineers, and industry stakeholders from other consortia with shared interests. The primary objective of “DECODE-GBM-Med” is to create a strategic networking event in September 2026 that will establish a forum for leveraging our strengths to decode the complex biology of glioma, understand the underlying mechanisms, and stratify patients to advance personalised glioma medicine. As a result, basic researchers will elucidate the mechanisms of GBM biology, multi-omics experts will decode the readouts and biomarkers, chemical biologists will identify the targets, clinicians will assess the relevance of the findings and their applicability in the clinical setting, and stakeholders will take steps to facilitate market research and implementation.